Clinical efficacy and safety of sintilimab injection plus chemotherapy in patients with stage IB–IIIB non-small cell lung cancer
The combination therapy of sintilimab injection, albumin-bound paclitaxel, and cisplatin for stage IB-IIIB NSCLC can effectively reduce tumor marker levels, improve immune function, demonstrating favorable clinical and pathological efficacy without increasing the incidence of adverse drug reactions.
Authors
- Qiang Guo (ORCID: https://orcid.org/0009-0002-0644-350X)
- Mingbo Wang
- Haijun Wang (ORCID: https://orcid.org/0000-0002-4935-3769)
- Ziqiang Tian
- Yanzhao Xu (ORCID: https://orcid.org/0000-0003-1333-5486)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Xingtai People's Hospital (CN)
- Affiliated Hospital of Hebei University (CN)
Publication Details
- Journal
- Pakistan Journal of Medical Sciences
- Published
- 2025-02-21
- DOI
- https://doi.org/10.12669/pjms.41.3.9830
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00